Otis W. Brawley, MD; Llewellyn J. Cornelius, PhD, LCSW; Linda R. Edwards, MD; Vanessa Northington Gamble, MD, PhD; Bettye L. Green, RN; Charles Inturrisi, PhD; Andra H. James, MD, MPH; Danielle Laraque, MD; Magda Mendez, MD; Carolyn J. Montoya, RN, MSN, CPNP; Brad H. Pollock, MPH, PhD; Lawrence Robinson, MD, MPH; Aaron P. Scholnik, MD; Melissa Schori, MD, MBA
Promote models of care (such as comprehensive care, medical home, family-centered) across the lifespan that support quality of care and improved access to evidence-based treatment, including hydroxyurea.
Provide multidisciplinary care (for example, from health educators, social workers, case managers, physicians, and nurses) to improve the physical and mental health of patients with sickle cell disease and the financing structures to support such care.
Provide support for community health worker models (such as patient navigators, patient advocates, and peer advocates).
Provide support for coordination and comanagement of patients with the use of telemedicine.
Ensure better translation of findings to the patient and caregiver populations by using culturally or language-appropriate written and visual materials.
Implement health promotion models in educational interventions for adherence to therapies.
Engage and support community-based efforts to improve knowledge of the benefits and risks of hydroxyurea.
Improve federal, state, and local coordination of activities regarding sickle cell disease.
Provide support for cultural competency training across the interdisciplinary team regarding care for sickle cell disease.
Improve insurance coverage of sickle cell disease (for example, extend Medicare coverage to adults with sickle cell disease who are younger than 65 years).
Eliminate barriers that restrict access to public insurance.
Support ongoing training of health professionals to achieve and maintain competence in the care of patients with sickle cell disease, including hydroxyurea treatment.
Increase funding by government, industry, and philanthropic organizations for patients with sickle cell disease.
Encourage partnership and support of advocacy groups for sickle cell disease.
Develop enhanced information systems to better coordinate delivery of care in the health care system.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Brawley OW, Cornelius LJ, Edwards LR, Gamble VN, Green BL, Inturrisi C, et al. National Institutes of Health Consensus Development Conference Statement: Hydroxyurea Treatment for Sickle Cell Disease. Ann Intern Med. ;148:932–938. doi: 10.7326/0003-4819-148-12-200806170-00220
Download citation file:
Published: Ann Intern Med. 2008;148(12):932-938.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use